Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 5/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | BCHE | P06276 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29495812 | 1.00 | PARP1 (0.35) | PARP1CDK2CDK9NOS3ACHE | |
| SCHEMBL22969403 | 0.91 | PARP1 (0.43) | PARP1NOS3HASPINMAP4K1 | |
| SCHEMBL29495954 | 0.91 | PARP1 (0.43) | PARP1NOS3HASPINMAP4K1 | |
| SCHEMBL24671043 | 0.86 | NOS3 (0.35) | PARP1CDK2CDK9NOS3ACHE | |
| SCHEMBL22969570 | 0.84 | CDK2 (0.36) | PARP1CDK2CDK9NOS3ACHE | |
| SCHEMBL29495957 | 0.84 | CDK2 (0.36) | PARP1CDK2CDK9NOS3ACHE | |
| SCHEMBL29496081 | 0.83 | CDK2 (0.35) | PARP1CDK2CDK9NOS3ACHE | |
| SCHEMBL29495802 | 0.78 | CHEK2 (0.43) | MAP4K1 | |
| SCHEMBL22969620 | 0.78 | CHEK2 (0.43) | MAP4K1 | |
| SCHEMBL3396520 | 0.71 | ADORA2A (0.36) | PARP1CDK2CDK9NOS3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-09-22 | — | — | US | disclosed |
| WO-2021023813-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | NPFFR2, NPFFR1, OPRL1 | PARP1 3040/4885CDK2 3050/4885CDK9 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.